Fam-trastuzumab deruxtecan-nxki | New Drug Approvals
Structures of antibody–drug conjugates (ADCs) and released payloads.... | Download Scientific Diagram
IJMS | Free Full-Text | HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer | HTML
,%20Lung%20Neoplasms:%0A%0ATrastuzumab%20deruxtecan%20(DS-8201a)%20for%20Carcinoma,%20Non-Small-Cell%20Lung.png?md=1 "Trastuzumab deruxtecan (DS-8201a) for Carcinoma, Non-Small-Cell Lung Clinical Trial | Power")
Trastuzumab deruxtecan (DS-8201a) for Carcinoma, Non-Small-Cell Lung Clinical Trial | Power
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | NEJM
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology
Debbrah clinical trial | MEDSIR
Antibody drug conjugate: the “biological missile” for targeted cancer therapy | Signal Transduction and Targeted Therapy
![iPoster : [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: a phase 3, randomized trial (](https://assets.posterview.com/SABCS/2019/1/Jpg/f/OT1-07-01.jpg "iPoster : [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: a phase 3, randomized trial (")
iPoster : [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: a phase 3, randomized trial (
Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond | npj Breast Cancer
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology
NCT02564900 (Clinical Trials/ DS-8201a) » ADC Review
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer | British Journal of Cancer
ADC Drug DS-8201 Shows Strong Efficacy in Patients with Low HER2 Breast Cancer Expression – Creative Biolabs ADC Blog
Antitumor immunity caused by combination of DS-8201a and anti-CTLA-4... | Download Scientific Diagram
DESTINY-Breast01 - Capsule Summary Slidesets - Breast Cancer - 2019 SABCS - Oncology - Clinical Care Options
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985) - ScienceDirect
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | NEJM
